<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04036214</url>
  </required_header>
  <id_info>
    <org_study_id>NSUOCO0001</org_study_id>
    <nct_id>NCT04036214</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Outcomes of Optometrist Performed Selective Laser Trabeculoplasty (SLT)</brief_title>
  <acronym>SLT</acronym>
  <official_title>Selective Laser Trabeculoplasty (SLT): Efficacy and Safety Outcomes of Optometrist (OD) Performed SLT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northeastern State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northeastern State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To measure the efficacy and safety outcomes of SLT performed by optometrists.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will undergo a pre-procedure examination in order to record baseline findings
      and to determine if they meet the inclusion criteria in order to undergo the procedure.
      Participants will undergo the SLT procedure and will be examined at 1 hour, 1 week and 6
      weeks. Follow up examinations will evaluate eye pressure reduction and post-procedure
      complications. The rate complication post-procedure are typically low.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 21, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular Pressure via Goldmann tonometry</measure>
    <time_frame>6 weeks</time_frame>
    <description>Pre and Post Procedure Intraocular Pressure will be measured using a Goldmann tonometer and will be measured in millimeters of Mercury (mmHg). Percent change in intraocular pressure will be determined.</description>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Primary Open-Angle Glaucoma, Unspecified Eye</condition>
  <condition>Ocular Hypertension</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Selective Laser Trabeculoplasty</intervention_name>
    <description>Selective Laser Trabeculoplasty Laser</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Existing patients at primary eye care optometric facilities.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability to provide written informed consent;

          2. At least 18 years of age, male or female, of Native American or Alaskan Native
             descent;

          3. Diagnosed with primary open angle glaucoma or ocular hypertension;

          4. Documented intraocular pressure greater than or equal to 23 mmHg;

          5. No prior glaucoma treatment unless treated with one topical drop.

        Exclusion Criteria:

          1. History of trauma or ocular surgery within the last 6 months;

          2. History of corneal dystrophy;

          3. Current use of topical or systemic steroids;

          4. Advanced or severe glaucomatous findings based on comprehensive examination;

          5. Diagnosed with other types of glaucoma such as pseudoexfoliation syndrome, pigmentary
             glaucoma, normal tension glaucoma, and other additional glaucoma subtypes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jeff M Miller, OD</last_name>
    <phone>918-444-4000</phone>
    <email>millerjm@nsuok.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nate Lighthizer, OD</last_name>
    <phone>918-444-4000</phone>
    <email>lighthiz@nsuok.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northeastern State University</name>
      <address>
        <city>Tahlequah</city>
        <state>Oklahoma</state>
        <zip>74464</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeff M Miller, OD</last_name>
      <phone>918-444-4000</phone>
      <email>millerjm@nsuok.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nate Lighthizer, OD</last_name>
      <phone>918-444-4000</phone>
      <email>lighthiz@nsuok.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 17, 2019</study_first_submitted>
  <study_first_submitted_qc>July 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2019</study_first_posted>
  <last_update_submitted>August 21, 2019</last_update_submitted>
  <last_update_submitted_qc>August 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

